前列腺特异性抗原和前列腺酸性磷酸酶血清水平在监测前列腺癌中的临床应用

Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer.

作者信息

Morote J, Ruibal A, Palou J, de Torres J A, Soler-Roselló A

机构信息

Service of Urology, C.S. Valle de Hebròn, Barcelona, Spain.

出版信息

Int J Biol Markers. 1988 Jan-Mar;3(1):23-8. doi: 10.1177/172460088800300105.

DOI:10.1177/172460088800300105

PMID:2470838

Abstract

We analysed 696 prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum samples by double antibody radioimmunoassay (RIA)I125 in the follow-up of 122 patients with prostate cancer under treatment. PSA levels were significantly correlated to response to treatment, whereas PAP results did not differentiate patients with partial or complete remission. Progression of the disease was detected in 95.2 and 85.4% of PSA and PAP samples, and increased to 99.9% using both simultaneously. On the whole, PSA was better than PAP in monitoring prostate cancer, and the efficacy was greater using both markers together.

摘要

我们采用¹²⁵I双抗体放射免疫分析法（RIA）对122例接受治疗的前列腺癌患者进行随访，分析了696份前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）血清样本。PSA水平与治疗反应显著相关，而PAP结果无法区分部分缓解或完全缓解的患者。在95.2%的PSA样本和85.4%的PAP样本中检测到疾病进展，同时使用两者时这一比例增至99.9%。总体而言，在监测前列腺癌方面PSA优于PAP，同时使用两种标志物时效果更佳。